Increased expression of plasminogen activator inhibitor -1 (PAI-1) in adipose tissues is thought to contribute to both the cardiovascular and metabolic complications associated with obesity. Tumor necrosis factor α (TNF-α) is chronically elevated in adipose tissues of obese rodents and humans and has been directly implicated to induce PAI-1 in adipocytes. In this study, we used 3T3-L1 adipocytes to examine the mechanism by which TNF-α up-regulates PAI-1 in the adipocyte. Acute (3 h) and chronic (24 h) exposure of 3T3-L1 adipocytes to TNF-α induces PAI-1 mRNA by increasing the rate of transcription of the PAI-1 gene, and de novo protein synthesis is not required for this process. Although the p44/42 and PKC signaling pathways appear to be significant in the induction of PAI-1 mRNA in response to acute treatment with TNF-α, the more dramatic induction of PAI-1 mRNA observed in response to chronic exposure of adipocytes to TNF-α was mediated by these and additional signaling molecules, including p38, PI3-kinase, tyrosine kinases, and the transcription factor NF-κB. Moreover, the dramatic increase in PAI-1 observed after chronic exposure of adipocytes to TNF-α was accompanied by increased metabolic insulin resistance. Finally, we demonstrate that the PKC pathway is also central for PAI-1 induction in response to insulin and transforming growth factor-β (TGF-β), two additional molecules which are elevated in obesity and shown to directly induce PAI-1 in the adipocyte. The understanding of the mechanism of regulating PAI-1 expression in the adipocytes at the molecular level provides new insight to help identify novel targets in fighting the pathological complications of obesity.
Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of plasminogen activation in vivo, and increased plasma PAI-1 compromises normal fibrin clearance mechanisms and promotes thrombosis (3) . PAI-1 levels have consistently been shown to be dramatically upregulated in obese humans (4) and is thought to be the link between obesity, insulin-resistance, and increased risk for cardiovascular disease. Increased levels of plasma PAI-1 in obese humans correlates strongly with parameters of the insulin-resistance syndrome, including body mass index, visceral fat, blood pressure, and plasma insulin levels (5). Interestingly, recent studies using PAI-1-deficient genetic and diet-induced obese mice also have demonstrated a role for PAI-1 in the development of obesity and insulin resistance itself (6, 7). Thus, the picture that is emerging is that elevated PAI-1 may be central to both the development of the obese phenotype and its metabolic, as well as cardiovascular consequences, and reduction of PAI-1 production may therefore be clinically useful. Elucidation of the extra cellular mediators and intracellular signaling pathways promoting the increase in PAI-1 will be the key to identifying novel therapeutic targets for the reduction of PAI-1 associated with obesity.
During the last several years the role of adipose tissue in contributing to obesity-associated cardiovascular and metabolic risk has gained much attention (8) . Adipose tissues secrete a variety of hormones, cytokines, and proteins that affect both insulin-sensitivity and cardiovascular risk (9) (10) (11) (12) . PAI-1 is dramatically elevated in adipose tissues of obese mice and humans, and adipose PAI-1 is considered to be an important contributor to elevated plasma PAI-1 associated with obesity (5, [13] [14] [15] [16] [17] .
Tumor necrosis factor α (TNF-α) is also chronically elevated in adipose tissues of obese rodents and humans (18), and several studies indicate that TNF-α may be a direct contributor to elevated PAI-1 in obesity. Specifically, TNF-α stimulates PAI-1 biosynthesis in a variety of cell types, including 3T3-L1 adipocytes (16, 19) . Intraperitoneal administration of TNF-α into lean mice increases PAI-1 mRNA in adipose tissues reminiscent of the pattern of cellular expression observed in obese mice (19) . Human adipose tissue explants and adipocytes respond to exogenous TNF-α with increased PAI-1 expression and addition of pentoxifylline (a methylxanthine known to inhibit TNF-α) decreases basal and TNF-α-induced PAI-1 levels (20) . Finally, inhibition of TNF-α in vivo by infusion of neutralizing antibodies, or deletion of both the p55 and p75 TNF-α receptors in obese (ob/ob) mice led to a decrease in both plasma and adipose tissue PAI-1 levels (21, 22) . Although these results directly implicate TNF-α in the elevated PAI-1 expression observed in plasma and adipose tissues in obesity, little is known regarding the molecular mechanisms and signaling events that mediate the regulation of PAI-1 by TNF-α in the adipocyte.
In the present study, we investigated the molecular mechanisms and signaling pathways by which TNF-α induces PAI-1 in adipocytes. We show that both acute (3 h) and chronic (24 h) exposure of 3T3-L1 adipocytes to TNF-α induces PAI-1 mRNA by increasing the rate of transcription of the PAI-1 gene. The p44/42 and PKC signaling pathways were important in the induction of PAI-1 mRNA in response to acute treatment with TNF-α. Interestingly, chronic exposure of adipocytes to TNF-α resulted in a more dramatic induction of PAI-1 mRNA mediated through additional signaling molecules including p38, PI3-kinase, tyrosine kinases and the transcription factor NF-κB. The dramatic increase in PAI-1 observed after chronic exposure of adipocytes to TNF-α was also intimately associated with metabolic insulin resistance. Finally, we demonstrate that the PKC pathway is central for PAI-1 induction in adipocytes not only in response to TNF-α, but also in response to insulin and transforming growth factor-β (TGF-β), which also are elevated in obesity (9, 23) and have been demonstrated to induce PAI-1 by the adipocyte (5, 23).
MATERIALS AND METHODS

Cell culture
3T3-L1 mouse embryo fibroblasts were obtained from the American Type Culture Collection (Rockville, MD). The culturing of these cells and their differentiation from preadipocytes to mature adipocytes was carried out as described previously (19, 24) . TNF-α treatment was carried out after a 24 h pretreatment in serum-free medium containing 0.2% bovine serum albumin (BSA). Cells were harvested 3 or 24 h later, and PAI-1 mRNA expression determined by realtime RT-PCR. In some experiments, the cells were pretreated with various inhibitors of TNF-α-initiated signaling pathways (wortmannin, PD98059, SB203580, DJNK1, GF109203X, genistein, and H8 from Calbiochem (La Jolla, CA); SN50 from Alexis Biochemicals, Lüufelingen, Switzerland) for 1 h before administration of TNF-α. Total RNA was isolated 3 or 24 h after TNF-α treatment using the Ultraspec RNA isolation system according to manufacturer's directions (Biotecx Laboratories, Inc., Houston. TX), and the relative level of PAI-1 mRNA was determined using real-time RT-PCR.
For the determination of PAI-1 mRNA stability, adipocytes were stimulated with TNF-α (8 ng/ml) for 1 h and then treated with actinomycin-D (5 µg/ml). After the addition of actinomycin-D cells were harvested at 1, 2, and 3 h for real-time RT-PCR analysis to determine PAI-1 gene expression. To determine whether de novo protein synthesis is required for TNF-α-mediated PAI-1 expression, adipocytes were treated with TNF-α (8 ng/ml) and cycloheximide simultaneously (2 µg/ml). Cells were harvested 3 h later and PAI-1 mRNA levels determined by real-time RT-PCR.
PAI-1 mRNA and heteronuclear RNA (hnRNA) expression by real time RT-PCR
For real-time RT-PCR, cDNA was prepared from 1 µg of total RNA using random hexamers and Moloney murine leukemia virus reverse transcriptase (PE Applied Biosystems, Foster City, CA) in a final reaction volume of 20 µl. The conditions for PCR for both PAI-1 mRNA, PAI-1 hnRNA, and β-actin mRNA were as follows. Real-time RT-PCR amplifications were performed from 2.5 µl cDNA diluted 1:2 using each of the gene-specific primer sets (Invitrogen Life Technologies, Grand Island, NY), as described previously (12, 22) . Each primer set was used at a concentration of 150 nM in a final volume of 25 µl using the SYBR® Green Master Mix (PE Applied Biosystems). All PCR reactions were performed in an iCycler (Bio-Rad laboratories, Hercules, CA). Quantification of PAI-1 mRNA, expressed as relative mRNA levels compared with a control, was calculated after normalization to β-actin and using the ∆∆C T formula as described by PE Applied Biosystems. Individual C T values are means of duplicate measurements. Separate control experiments demonstrated that the efficiency of target and reference amplification were equal. The specificity of the PCR-amplification was verified by melt-curve analysis of the final products directly in the iCycler and also by agarose-gel electrophoresis.
PAI-1 ELISA
PAI-1 antigen levels in the medium of control and TNF-α treated 3T3-L1 adipocyte cell cultures were determined by an ELISA assay. Briefly, microtiter wells were coated with a monoclonal anti-mouse PAI-1 antibody (1 µg/ml in PBS; a kind gift from Dr. D. Collen, Center for transgene technology and gene therapy, Katholieke Universiteit Leuven) by overnight incubation at 4°C. After blocking with 3% casein in PBS, appropriately diluted samples were added and allowed to bind for 1 h at 37°C. The wells were washed with PBS, and bound PAI-1 was detected with rabbit anti-murine PAI-1, followed sequentially with biotinylated goat anti-rabbit (Zymed, San Francisco, CA), streptavidin-alkaline phosphate conjugate (Zymed) and p-nitrophenyl phosphate (Zymed) as substrate. The OD 405 was measured using a microplate reader (Molecular Devices, Palo Alto, CA). Samples were compared with a standard curve of recombinant murine PAI-1.
Measurement of 2-deoxyglucose uptake
Glucose uptake was measured by assaying 3 H-labeled 2-deoxyglucose uptake, as described previously with minor modifications (25, 26) . Briefly, 24 h before measurement of glucose transport, adipocytes grown and differentiated in 6-well culture plates were placed in serum-free DMEM containing 0.2% BSA. On the day of the experiment, cells were washed twice with phosphate-buffered saline (PBS) and incubated in serum-free media with 0.2% BSA for 2 h. This washing/incubation procedure was repeated twice more but with 1 h incubations. No significant differences in insulin-mediated glucose transport were observed when the glucose transport assay was carried out in the presence or absence of TNF-α (data not shown). Glucose transport assays were therefore routinely carried out in the absence of TNF-α. To initiate glucose transport, the media was removed and the cells were incubated in 1 ml/well Krebs-Ringer Phosphate buffer containing 100 nM insulin for 20 min at 37°C. Radiolabeled glucose (1 µCi/ml 2-deoxy-d- [1, 2- 3 H] glucose; Dupont NEN), was added and the cells were incubated another 20 min at 37°C. The assay was terminated by removing the media and rapidly washing the cells three times with ice-cold PBS. The monolayers were solubilized in 1 ml of 10% SDS, and the counts per minute (cpm) in the extracts were determined by liquid scintillation counting. Nonspecific glucose uptake was determined in parallel samples treated with 100 µM cytochalasin B, and this background cpm was subtracted from total cpm.
Statistical analysis
Statistical comparisons of results were performed using the unpaired Student's t test.
RESULTS
PAI-1 induction in 3T3-L1 adipocytes in response to acute and chronic TNF-α treatment
Fully differentiated 3T3-L1 adipocytes were treated either for 3 (acute) or 24 (chronic) hours with recombinant mouse TNF-α (8 ng/ml). Total RNA was extracted from the adipocyte monolayers, and PAI-1 and β-actin mRNA expression levels were determined using real-time RT-PCR. PAI-1 antigen secreted into the conditioned medium was determined by an ELISA assay as described in Materials and Methods. As we previously observed (19) , acute treatment of 3T3-L1 adipocytes for 3 h with TNF-α resulted in a sixfold increase in the levels of PAI-1 mRNA (Fig. 1A) . There was no detectable increase in the level of PAI-1 antigen in the conditioned medium (Fig. 1B) . Chronic treatment of adipocytes with TNF-α resulted in a 12-fold increase in PAI-1 mRNA expression levels and a fivefold increase in PAI-1 antigen secreted into the medium.
In addition to inducing PAI-1, TNF-α has been shown to be involved in the development of metabolic insulin resistance (27, 28) . Because elevated PAI-1 has been consistently associated with insulin resistance, and adipocytes treated for 24 h with TNF-α showed a higher induction of PAI-1 when compared with adipocytes treated for 3 h, we wanted to determine the insulin sensitivity of adipocytes 24 h after TNF-α treatment. We hypothesized that 24 h treatment with TNF-α was sufficient to render these adipocytes metabolically insulin-resistant and that this was closely linked to higher induction of PAI-1 observed in these cells. Indeed, insulin-mediated glucose uptake assays indicate that 24 h of TNF-α treatment causes a significant decrease (P<0.0001) in insulin-mediated glucose transport ( Fig. 1C ) with a concurrent increase in PAI-1 mRNA and protein expression (Fig. 1A, B) .
Effect of TNF-α on PAI-1 mRNA stability and transcription in adipocytes
To determine the mechanism for increased PAI-1 mRNA levels in TNF-α-treated cells, we tested mRNA stability and degradation using fully differentiated 3T3-L1 adipocytes. The cells were pretreated with TNF-α for 1 h and then incubated with the transcription inhibitor actinomycin D for 0, 1, 2, and 3 h. Total RNA was extracted and analyzed by real-time RT-PCR to determine the level of PAI-1 transcripts. As shown in Fig. 2A , PAI-1 mRNA expression in cells treated with TNF-α and actinomycin D was significantly lower than in cells treated with TNF-α alone, suggesting that TNF-α does not increase the stability of the PAI-1 message in adipocytes. The half-life of PAI-1 mRNA in untreated cells was 50 min and 49 min in cells treated with TNF-α (Fig. 2B) . Similarly, there was no difference in the rate of PAI-1 mRNA degradation between normal adipocytes (i.e., adipocytes treated acutely for 3 h with TNF-α) or insulin-resistant adipocytes (i.e., adipocytes treated chronically for 24 h with TNF-α). These data suggest that differences in PAI-1 mRNA stability do not contribute to the TNF-mediated increase in PAI-1 expression in either normal or in insulin-resistant adipocytes.
We used a heteronuclear RNA (hnRNA) assay (29, 30) to determine whether the increase in PAI-1 mRNA expression after acute or chronic TNF-α treatment of adipocytes reflected an increase in the rate of transcription of the PAI-1 gene. In this assay, heteronuclear PAI-1 RNA was measured using intron-specific PAI-1 primer sequences in total RNA extracted from adipocytes that were treated for either 3 or 24 h with TNF-α. As shown in Fig. 2D , when compared with untreated cells, PAI-1 hnRNA levels were significantly higher in adipocytes treated for either 3 or 24 h, respectively, with TNF-α. Together with there being no change in RNA stability or degradation, these results suggest that the increased steady state PAI-1 mRNA levels observed after TNF-α treatment are a result of increased transcription of the PAI-1 gene.
We next determined whether de novo protein synthesis was required for the induction of PAI-1 mRNA by TNF-α in adipocytes. Total RNA was isolated from 3T3-L1 adipocytes that had been incubated for 3 h with or without TNF-α (8 ng/ml) in the presence or absence of cycloheximide (2 µg/ml). This concentration of cycloheximide, inhibited L-[
35 S]methionine incorporation in adipocytes by >99% (data not shown). As shown in Fig. 3A , TNF-α-induced PAI-1 mRNA expression was not blocked by cycloheximide, indicating that de novo protein synthesis is not required for the induction of PAI-1 by TNF-α. Instead, PAI-1 mRNA accumulation was further induced (i.e., super induced) in the presence of cycloheximide. Incubation of 3T3-L1 adipocytes with cycloheximide alone also significantly increased the level of PAI-1 mRNA. Incubation with cycloheximide did not change the expression levels of β-actin under these conditions (data not shown). Because cycloheximide appears to stabilize some mRNA (31, 32) , experiments were performed to determine whether our observed cycloheximide-induced increase in PAI-1 mRNA reflected an increase in the stability of the PAI-1 message in adipocytes. As indicated in Fig. 3B , treatment of adipocytes with cycloheximide (2 µg/ml) and actinomycin D (5 µg/ml) did not inhibit PAI-1 mRNA expression when compared with cells treated with cycloheximide alone, suggesting that the cycloheximide-mediated increase in PAI-1 mRNA levels is a result of an increase in stability of the PAI-1 message. Experiments performed to determine the rate of decay of PAI-1 mRNA indicated that the half-life of PAI-1 mRNA in control cells was 50 min, while the half life of PAI-1 mRNA in cycloheximide treated cells was more than 3 h, again suggesting that cycloheximide increases the stability of the PAI-1 message in adipocytes. These experiments using the protein synthesis inhibitor cycloheximide (Fig. 3) indicate that the effects of TNF-α on PAI-1 expression do not require new protein synthesis but may reflect post-transcriptional modifications such as phosphorylation of kinases.
Signaling pathways used by TNF-α for the induction of PAI-1 in adipocytes
TNF-α activates several signaling molecules, including the MAP kinases (i.e., the p44/42, p38, and JNK/SAPK), PI-3 kinase, tyrosine kinases, PKC, and the nuclear factor NF-κB (33, 34) . We (data not shown) and others have shown that all of these signaling pathways are activated by TNF-α in adipocytes (35) . Specific inhibitors of these distinct TNF-α signaling pathways were used to begin to dissect the molecular mechanisms by which TNF-α induces PAI-1 in adipocytes.
3T3-L1 adipocytes were either left untreated or were preincubated for 1 h with each of the inhibitors specific for each pathway at the indicated concentrations, as described in Materials and Methods. PAI-1 mRNA levels were determined either 3 h (acute, Fig. 4A ) or 24 h (chronic, Fig.  4B ) after subsequent treatment with TNF-α. Cell viability was not affected under these conditions (measured using the LDH cytotoxicity detection kit; Roche, data not shown). Preincubation of cells with the p44/42 inhibitor PD98059 inhibited PAI-1 mRNA levels both in response to acute (P<0.02) and chronic (P<0.02) treatment with TNF-α. Preincubation with the p38 inhibitor SB203580 inhibited PAI-1 mRNA expression levels only in response to chronic TNF-α treatment (P<0.03). Inhibition of JNK or PKA had no effect on the expression levels of PAI-1 in adipocytes (data not shown). None of these inhibitors significantly changed the basal expression of PAI-1 mRNA in adipocytes (data not shown). These studies suggest that while PAI-1 mRNA induction in response to short-term acute exposure (3 h) to TNF-α primarily uses the p44/42 MAP kinase pathway, the more dramatic induction of PAI-1 mRNA observed after long-term, chronic (24 h) exposure of adipocytes to TNF-α appear to be mediated by both the p44/42 and p38 MAP kinases. Interestingly, in adipocytes treated chronically with TNF-α (insulin-resistant adipocytes) inhibition of the MAP kinases p44/42 and p38 did not inhibit TNF-α stimulated PAI-1 mRNA to basal levels, suggesting that in these adipocytes, additional signaling cascades may participate in the PAI-1 response.
TNF-α also activates PI-3 kinase, various tyrosine kinases and the PKC signaling pathways in adipocytes (35) (36) (37) . Specific inhibitors of these signaling pathways also were used to investigate their roles in TNF-α-mediated PAI-1 mRNA expression in the adipocyte. Wortmannin, a specific inhibitor of PI-3 kinase, significantly inhibited PAI-1 mRNA expression in adipocytes treated chronically (24 h) with TNF-α (Fig. 4B, P<0 .017) with no significant effect on PAI-1 mRNA levels 3 h after TNF-treatment (P<0.26). Similarly, inhibition of tyrosine kinase by genestein reduced PAI-1 mRNA in adiopcytes chronically treated with TNF-α to a larger extent (Fig. 4B,  P<0 .002) than in adipocytes acutely treated with TNF-α (Fig. 4A, P<0.2) . Interestingly, a specific inhibitor to the transcription factor NF-κB (SN50) reduced PAI-1 mRNA only in cells treated with TNF-α for 24 h (P<0.05) and not in adipocytes acutely treated for 3 h with TNF-α. TNF-α has been shown to activate PKC in several cell types, including adipocytes (35, 38) . To investigate the role of PKC in TNF-α induced PAI-1 synthesis in adipocytes, we examined the effect of GF 109203X, a highly potent and specific inhibitor of PKC (39) on PAI-1 expression after acute and chronic exposure of adipocytes to TNF-α. Pretreating adipocytes with GF109203X almost totally inhibited TNF-α-induced PAI-1 mRNA induction in both the acute (P<0.019), and chronic (P<0.001) treatment conditions (Fig. 4A, B) . Figure 4C shows the effect of the various signaling inhibitors on PAI-1 antigen secreted into the medium 24 h after TNF-α treatment. PAI-1 antigen levels were significantly reduced when adipocytes were pretreated with the PI3-kinase inhibitor wortmannin (P<0.013) and the PKC inhibitor GF109203X (P<0.001).
Role of PKC in insulin and TGF-β induced expression of PAI-1 in adipocytes
Hyperinsulinemia and elevated levels of TGF-β are associated with obesity, and we previously demonstrated that both insulin and TGF-β are potent inducers of PAI-1 in adipose tissues and in the adipocyte (9, 25) . Because the PKC pathway appears to be central to the induction of PAI-1 by TNF-α in adipocytes, we questioned whether this pathway also was involved in the regulation of PAI-1 by insulin and/or TGF-β. As indicated in Fig. 5 , pretreating adipocytes with the PKC inhibitor GF109203X restored both insulin and TGF-β mediated PAI-1 mRNA expression levels to almost basal levels. Again, GF109203X alone had no significant effect on PAI-1 mRNA expression in adipocytes.
DISCUSSION
Previous observations in our laboratory have demonstrated that increased levels of TNF-α associated with obesity may be an important contributor to elevated plasma and adipose tissue expression of the procoagulant gene PAI-1. In the present study, we have extended our previous findings to investigate the molecular mechanisms by which TNF-α induces PAI-1 in the adipocyte. We demonstrate that 1) TNF-α increases PAI-1 mRNA in adipocytes through increased gene transcription without the need for de novo protein synthesis; 2) chronic exposure (24 h) of adipocytes to TNF-α results in a more dramatic and larger induction of PAI-1 than acute (3 h) exposure; 3) the magnitude of induction of PAI-1 by TNF-α in adipocytes is directly correlated with the degree of TNF-α-mediated metabolic insulin resistance, and finally, 4) PAI-1 mRNA expression in response to acute short term exposure to TNF-α is mediated primarily via the p44/42 and PKC signaling pathways, while PAI-1 expression due to chronic TNF-α exposure is mediated via these, as well as additional signaling pathways, including the p38, PI-3 kinase, tyrosine kinase, and NF-κB.
We have shown that 24-h chronic exposure of adipocytes to murine recombinant TNF-α resulted in a larger and more dramatic induction of PAI-1 than that observed when adipocytes were treated with TNF-α for only 3 h (Fig. 1) . This is in contrast to our previous studies where we demonstrated that chronic exposure of 3T3-L1 adipocytes to human recombinant TNF-α did not induce PAI-1 mRNA after 24 h of exposure (19) . This difference between these two results is likely attributable to the different affinity of murine and human TNF-α receptors. TNF-α signals through two receptors, a p55 kDa (p55) and a 75k Da (p75) form (40, 41) . It is known that human TNF-α binds to only the p55 TNFR on mouse cells while recombinant mouse TNF-α binds both the p55 and p75 TNF-α receptors (42) . Given the differential effects of TNF-α in our system, it appears that the p75 TNFR is essential for the long-term continued and chronic induction of PAI-1 by TNF-α. Consistent with this, it is significant to note that we previously demonstrated that in obese (ob/ob) mice both the p55 and the p75 TNFRs acted cooperatively to induce maximum PAI-1 mRNA expression in the adipose tissue, again suggesting an important role for the p75 TNFR in this response (22) .
The 3′ untranslated region of PAI-1 mRNA contains AU-rich sequences implicated in mRNA half-life (3), raising the possibility that increases in PAI-1 mRNA half-life in response to TNF-α treatment may account for its increased accumulation. However, experiments performed using the transcriptional inhibitor actinomycin D do not indicate that TNF-α increases the half-life of PAI-1 mRNA in either normal or in insulin-resistant adipocytes ( Fig. 2A, B, C) . Interestingly, the half-life of PAI-1 mRNA in adipocytes is shorter than what has been reported for other cell types. Although PAI-1 mRNA half-life in adipocytes is ~50 min (Fig. 2B, C) , the half-life for PAI-1 mRNA, in rat hepatoma cells is 4 h (43) , in HepG2 cells is 120 min (44) , and in human umbilical vein endothelial cells, the PAI-1 message is stable (45) . These differences likely reflect the existence of cell-specific post-transcriptional mechanisms that dictate the stability of the PAI-1 mRNA in a given cell type. Our data are thus consistent with the conclusion that the observed increases in steady-state PAI-1 mRNA levels in TNF-α-treated adipocytes result primarily from events at the level of transcription (Fig. 2D) . The rapid onset of induction and the lack of inhibition by cycloheximide (Fig. 3) suggest further that these events are primary in nature.
In this study, induction of PAI-1 mRNA by TNF-α in adipocytes was not blocked by the protein synthesis inhibitor cycloheximide, suggesting that de novo protein synthesis was not required for the PAI-1 response. In fact, treatment with cylcoheximide alone increased PAI-1 mRNA levels (Fig. 3) . Treatment with cycloheximide in combination with TNF-α caused a super induction of PAI-1 mRNA in adipocytes. Our studies demonstrating that cycloheximide can stabilize PAI-1 mRNA in adipocytes (Fig. 3C) provides a molecular explanation for this response. Although superinduction of the PAI-1 gene by cycloheximide has been reported for certain cell types (46) (47) (48) (49) (50) , in other cell types, this phenomenon has not been observed (51) (52) (53) (54) (55) . All of these studies underscore the existence of basic differences in the mechanisms underlying the regulation of PAI-1 mRNA by specific mediators in specific cell types.
Our studies using inhibitors of specific TNF-α signaling pathways (Fig. 4) clearly demonstrate that TNF-α regulates PAI-1 mRNA expression through different pathways in metabolically insulin-sensitive (adipocytes treated for 3 h with TNF-α) and in metabolically insulin-resistant (adipocytes treated for 24 h with TNF-α) cells. Adipocytes treated for 3 h with TNF-α appear to primarily require the activation of p44/42 and PKC for PAI-1 mRNA induction. Interestingly, the more dramatic induction of PAI-1 mRNA observed in adipocytes treated for 24 h with TNF-α was more complex. For example, besides the p44/42 MAPK and PKC pathways, these cells also appeared to utilize the p38 MAP kinase pathway, tyrosine kinases and a signaling cascade that required the activation of PI3-kinase and the transcription factor NF-κB. These results raise the intriguing possibility that chronic TNF-α exposure that one may encounter in situations like obesity may activate alternate and/or compensatory signaling pathway(s) for PAI-1 gene expression in the adipocyte. Alternatively, it could also mean that there may be crossing over between various signaling pathways in insulin-resistant adipocytes, or that the coordinated activation of multiple signaling pathways is necessary for the increased magnitude of PAI-1 gene expression observed in these cells. The possibility that secondary mediators may be involved in the PAI-1 response after chronic treatment with TNF-α also cannot be ruled out. Additional studies are required to resolve these questions and clarify the mechanisms involved. It should be noted that we previously demonstrated a similar phenomenon for PAI-1 induction by insulin in normal and in insulin-resistant adipocytes, in which the use of signaling pathways appears to change as adipocytes become metabolically insulin resistant (25) . In that instance, insulin induced PAI-1 expression in normal adipocytes via the p44/42 MAP kinase pathway, whereas in insulin-resistant adipocytes induction of PAI-1 by insulin used multiple pathways, including the p44/42 MAPK, PI3-kinase and p70 S6 kinase pathways. These findings underscore the importance of using caution when extrapolating results obtained using normal adipocytes to the situation in obese cells in which the adipocytes are insulin-resistant and thus behave differently in the usage of signaling pathways to mediate specific events.
Our studies on the signaling pathways used by TNF-α for PAI-1 induction in adipocytes have identified PKC as a central mediator of this response since inhibiting the PKC pathway almost completely inhibited both TNF-mediated PAI-1 mRNA (Fig. 4A, B) and PAI-1 antigen (Fig. 4C) . The fact that PKC inhibition almost completely abolished TNF-mediated PAI-1 mRNA induction suggests that the PKC pathway may be upstream of MAPK, PI3-kinase, and tyrosine kinase in the signaling cascades that lead to the induction of PAI-1 mRNA by TNF-α in adipocytes. Consistent with this hypothesis, in preliminary studies, we demonstrated that pretreating 3T3-L1 adipocytes with the PKC inhibitor GF109203X reduced the TNF-α-mediated activation of p44/42, p38, PI3-kinase, tyrosine kinase, and NF-κB (data not shown). The PKC family of serine/threonine kinases plays an important role in modulating a variety of biological responses ranging from regulation of cell growth to cell death (56) . The involvement of PKC in signal transduction of various biological responses mediated by TNF-α in different cell types, including adipocytes have been reported (57) (58) (59) (60) . Additionally, PKC also has been implicated in the development of insulin resistance in adipocytes (58) , suggesting that the TNF-α signaling pathways mediating insulin-resistance and PAI-1 expression in adipocytes overlap.
Previous studies have shown that PKC, tyrosine kinases, and MAP kinase may influence PAI-1 expression in mesangial cells, dermal fibroblasts, and HepG2 cells (61) (62) (63) . PKC-β and MAPK also were involved in the activation of PAI-1 synthesis by phorbol esters in human promyelocyte HL-60 cells (64) . In TNF-α-treated human endothelial cells the PKC pathway had only a moderate effect on PAI-1 expression (65) . On the other hand, the present study shows a significant role for PKC in the induction of PAI-1 by TNF-α in adipocytes. Thus, usage of PKC appears to be cell specific and/or alternatively, various isoforms of PKC may be responsible for these effects. The PKC inhibitor GF 109203X used in our studies is a broad spectrum inhibitor for a variety of PKC isozymes, which include PKCα, β1, β11, γ, δ, and ε. Studies aimed at identifying the specific isoforms of PKC involved in the TNF-α mediated elevation of PAI-1 in the adipocyte using isoform-specific inhibitors are currently ongoing.
In this study, adipocyte pre-treatment with genistein attenuated the increase of PAI-1 mRNA expression induced by chronic (24 h-insulin resistant) treatment with TNF-α. In various cells PAI-1 induction by TNF-α, basic fibroblast growth factor, insulin, and IGF involves a Genistein-sensitive pathway (66) (67) (68) (69) . Genistein is not only a tyrosine kinase inhibitor but also a flavonoid and has been shown to exert diverse effects on adipocyte biology, including inhibition of adipogenesis (70, 71) .
In addition to TNF-α, levels of insulin and TGF-β also are increased in obesity, and these molecules have been shown to induce PAI-1 biosynthesis in adipocytes (9, 19, 21) , suggesting that these mediators also may contribute to the elevated PAI-1 observed in obesity. Both insulin and TGF-β have been shown to use the PKC signaling pathway to elicit various biological responses (72) (73) (74) (75) . Our studies demonstrate that the PKC pathway also is used by adipocytes in the insulin and TGF-β induced expression of PAI-1. These studies suggest that the PKC pathway may be a common signaling pathway involved in the induction of PAI-1 not only by TNF-α but also by insulin and TGF-β, all of which are elevated in obesity and induce PAI-1 in the adipocyte.
In summary, these studies provide new information regarding the molecular mechanisms and signaling cascades in the adipocyte that lead to the induction of PAI-1, a gene that is consistently elevated in obesity, and not only an established risk factor for cardiovascular disease but may also contribute to the metabolic risk associated with obesity. Our results further suggest that PKC inhibitors may provide a means for down-regulating PAI-1 expression in adipocytes thereby diminishing both the cardiovascular and metabolic risk associated with obesity. 1 . Acute and chronic effects of tumor necrosis factor-α (TNF-α) on PAI-1 expression and glucose transport in 3T3-L1 adipocytes. 3T3-L1 adipocytes were grown and differentiated in 6-well culture plates, as described in Materials and Methods. For determination of PAI-1 expression, conditioned medium and total RNA were isolated from untreated control cells, and cells treated with 8 ng/ml recombinant mouse TNF-α for either 3 or 24 h. PAI-1 and β-actin mRNA expression was determined using real-time RT-PCR (A), and PAI-1 antigen in the conditioned medium was determined using an ELISA assay as described in Methods (B). For determination of insulin-mediated glucose transport, adipocytes were treated for either 3 or 24 h with 8 ng/ml recombinant mouse TNF-α, and 2-deoxy-d- [1, 2- 3 H] glucose uptake was determined in the presence or absence of 100 nM insulin, as described in Materials and Methods. For (A, B, and C) , n = 6 ± SD. adipocytes were grown and differentiated in 6-well culture plates, as described in Materials and Methods. For the determination of PAI-1 mRNA stability, adipocytes were pretreated with 8 ng/ml mouse recombinant TNF-α for 1 h (A, B, C), after which the cells were incubated with actinomycin D (5 µg/ml) for the indicated times. Cells were harvested (A, 3 h), and PAI-1 mRNA expression was determined on total RNA by real-time RT-PCR. For determination of PAI-1 mRNA transcription, total RNA was extracted from adipocytes treated either for 3 or 24 h with 8 ng/ml recombinant mouse TNF-α, and heteronuclear PAI-1 RNA expression was determined on total RNA by real-time RT-PCR using intron-specific PAI-1 primer sequences (D). For (A, B, C, and D) , n = 6 ± SD.
Page 18 of 21 (page number not for citation purposes) were grown and differentiated in 6-well culture plates, as described in Materials and Methods. A) Total RNA was isolated from adipocytes incubated for 3 h with 8 ng/ml recombinant mouse TNF-α in the presence or absence of cycloheximide (2 µg/ml). PAI-1 mRNA was determined using real-time RT-PCR. B, C) To determine whether cycloheximide induces PAI-1 mRNA stability, adipocytes were pretreated with 2 µg/ml cycloheximide, after which the cells were incubated with actinomycin D for the indicated times. Cells were harvested, and PAI-1 mRNA expression determined using real-time RT-PCR. For (A, B, and C), n = 6 ± SD. adipocytes were grown and differentiated in 6-well culture plates, as described in Materials and Methods. Adipocytes were pretreated for 1 h with DMSO or with 10 µg/ml GF109203X, after which the cells were treated either with 100 nM insulin (A) or 1 ng/ml TGF-β (B) for 3 h. PAI-1 mRNA expression was measured on total RNA using real-time RT-PCR. For (A and B), n = 6 ± SD.
